Form 4: BridgeBio Pharma CEO Neil Kumar Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Neil Kumar, CEO of BridgeBio Pharma, sold shares of common stock on February 25, 2025, under a pre-arranged Rule 10b5-1 sales plan.
Summary
- Neil Kumar, the CEO of BridgeBio Pharma, sold shares of the company's common stock on February 25, 2025.
- The sales were executed under a Rule 10b5-1 sales plan adopted on March 22, 2024.
- A total of 37,899 shares were sold at a weighted average price of $33.3636, with prices ranging from $32.63 to $33.61 per share.
- An additional 37,101 shares were sold at a weighted average price of $33.7868, with prices ranging from $33.635 to $34.18 per share.
- Following the transactions, Kumar directly owns 211,718 shares of common stock.
- Kumar also indirectly owns 5,023,447 shares through the Kumar Haldea Revocable Trust and 995,686 shares through the Kumar Haldea Family Irrevocable Trust, where he serves as a co-trustee.
- Kumar disclaims beneficial ownership of the shares held in the trusts except to the extent of his pecuniary interest.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock sales by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to sell shares under 10b5-1 plans to avoid accusations of trading on inside information.
Stakeholder Impact
- The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2024/03/22 | Date of adoption of Rule 10b5-1 sales plan |
| 2025/02/25 | Date of transaction (sale of shares) |
| 2025/02/27 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.